CJC-1295 without DAC and Ipamorelin: Short Windows on Two Receptors

The blend holds two peptides addressing two receptors. CJC-1295 without DAC - more accurately Modified GRF (1-29) - is a sermorelin analogue carrying four substitutions that resist enzymatic cleavage, without the albumin-binding drug affinity complex. Ipamorelin is a pentapeptide agonist at GHS-R1a. One ligand per receptor, both with short occupancy windows relative to the DAC form.

The naming confusion matters here. "CJC-1295" originally referred to the DAC conjugate; "CJC-1295 without DAC" is informal supply-side language for Modified GRF (1-29). The molecule in this vial is the short-acting GHRH analogue, not the multi-day albumin-bound form characterised by Teichman and colleagues.

Ipamorelin belongs to a different class. Raun and colleagues confirmed with antagonist pharmacology that it works through a GHRP-like receptor rather than the GHRH receptor, and reported that it did not raise ACTH or cortisol above GHRH-stimulated levels even at exposures more than two hundred-fold above its GH-releasing threshold.

As with the DAC pairing, the pharmacological argument for combining a GHRH analogue with a secretagogue is published and real.

Because GHRH-receptor and GHS-R1a agonists engage separate receptors, their combined effect on GH secretion need not be additive. Veldhuis and Bowers treat GHRH-GHRP synergy as an established phenomenon in controlled human work and characterise what modulates it - age, visceral fat and IGF-I explaining most of the variance.

The same two qualifications apply. The synergy literature was built with GHRH(1-29) or GHRH(1-44) and with GHRP-2 or GHRP-6, not with these exact molecules. And Tiulpakov's crossover found a combined response that exceeded either agent alone but was not significantly greater than the sum of the separate responses - a reminder that relative exposure can erase an expected synergy.

What distinguishes this blend from the DAC pairing is pharmacokinetics, not receptor logic. Both ligands here are short-window agonists. That may better approximate the pulse-like engagement endogenous GHRH produces - but that is an inference, not a measured claim about this vial.

The same 2026 review that reports CJC-1295 with ipamorelin in a murine glucocorticoid muscle-loss model is the only combination-specific datapoint located. It does not state that the GHRH analogue was the non-DAC form, so applying it to this vial is an extra inferential step beyond the already preclinical finding.

There is no combined pharmacokinetic study of Modified GRF (1-29) with ipamorelin. There is no ratio study. There is no human safety observation for the fixed-ratio lyophilisate.

Component literatures exist separately. Combination characterisation for this preparation does not.

The stated composition is 5 mg CJC-1295 without DAC and 5 mg ipamorelin. Molecular weights still skew molecule counts toward ipamorelin; no published work identifies an appropriate molar ratio of GHRH analogue to secretagogue for a fixed vial.

The honest evidence position is close to the DAC blend's, with one difference: this GHRH arm lacks the Teichman human pharmacokinetics package that anchors the DAC form. The two-receptor rationale is shared; the depth of human characterisation of the GHRH component is not.

Anyone evaluating this product against the DAC / Ipamorelin blend should ask which GHRH-arm exposure profile their study design actually needs - sustained albumin-bound engagement, or a short window - rather than treating the two vials as interchangeable.